多系統萎縮症の標準的治療と新規治療

DOI

書誌事項

タイトル別名
  • Standard treatment and novel treatment for multiple system atrophy

この論文をさがす

説明

<p>Multiple system atrophy (MSA) is a refractory neurodegenerative disease and at present no fundamental therapeutic method has been found, but due to the progress of research in recent years, development of new therapeutic regimens is expected in the future. Treatment methods that can be selected in Japan as of 2018 are symptomatic treatments such as TRH analogs, drugs for treating Parkinson's disease, vasopressors, drugs for dysuria disorder etc. Non–medication therapy includes treatment such as rehabilitation, non–invasive ventilation therapy, tracheostomy, ventilation, and gastrostomy. Clinical trials targeting humans have failed to demonstrate the inhibitory effect on progression, but as a future treatment, COQ10 treatment, mesenchymal stem cell transplantation, treatment targeting α–synuclein, etc. are expected. In future clinical trials, it is important to set up an appropriate clinical trial plan with the precise pathological condition modifying mechanism as the background, and appropriate clinical study plan such as severity, evaluation index, biomarker, treatment start time, drug dose setting etc.</p>

収録刊行物

  • 神経治療学

    神経治療学 36 (4), 354-358, 2019

    日本神経治療学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ